The Coronavirus Disease of 2019: Prevention, Management and Treatment Strategies
Nkechi E. Egbe, Chukwu C. Onyedikachi, Ashiru M. Dantata, Surajo Jamaliddeen, Amaka M. Awanye
Journal of Advances in Biology & Biotechnology · pp. 12–24 · Published 15 Feb 2021
10.9734/jabb/2021/v24i130193Abstract
The recent COVID-19 pandemic caused by the novel coronavirus (SARS-CoV2) has taken the world by surprise since its outbreak in 2019, and as on February 2021, the world had experienced a total of 107,643,141 (one hundred and seven million, six hundred and forty-three thousand, one hundred and forty-one) confirmed infection cases and 2,358,244 (two million, three hundred and fifty-eight thousand, two hundred and forty-four) deaths world-wide. This virus, although less lethal than the previous human coronaviruses (SARS-CoV and MERS-CoV), is reported highly infectious and mutable. This has led to a concerted effort by numerous governments and private organisations to try and halt the spread of the virus through the development of highly effective therapeutic drugs or prophylactic therapy. There are various drugs, vaccines and other forms of therapies currently being developed all over the world, with some at various clinical trial stages, with only one (Remdesivir) being fully approved treatment of the COVID-19 disease. The latest breakthrough with Dexamethasone has currently revealed the efficacy of the drug in treating critically ill and even mechanically ventilated COVID-19 patients, and this has led to the approval of the drug by the United Kingdom and World Health Organization (WHO). The recent development of a protective SARS-CoV-2 vaccine has created hope for life and restoration of normalcy.
Cited by 1
Yahaya Abdullahi Umar, Uthman Umar Shanono, Ugochukwu Okechukwu Ozojiofor · Journal of Umm Al-Qura University for Applied Sciences · 2025
Related research
- Covid-2019:“A Microbiological Monster” — shares topic coverage
- COVID 19 Disease Caused by Coronavirus 2 (SARS-CoV-2) (Severe Acute Respiratory Syndrome) — shares topic coverage
- Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): What Can Africa Learn from Ongoing Research in Epidemiology, Clinical Manifestations, Chemotherapy and Prevention? — shares topic coverage
- Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19 — shares topic coverage
- Early Treatment with Hydroxychloroquine Improves Clinical Outcomes and Reduces Hospital Admissions in COVID-19 Associated Pneumonia — shares topic coverage
Article metrics
Real usage data collected on this platform.
0
Page views
0
PDF downloads
0
Outbound clicks
1
Citations
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
No views recorded yet.
Traffic sources
Referring site, by host.
No traffic recorded yet.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.